1075753-27-3

Usage

Uses

Used in Pharmaceutical Applications:
1H-Benzimidazole, 2-chloro-7-(trifluoromethyl)is used as a pharmaceutical intermediate for the development of new drugs due to its various biological activities, including antifungal, antibacterial, and antiproliferative properties. Its unique structure and functional groups make it a promising candidate for the synthesis of compounds with therapeutic potential.
Used in Research Applications:
In the field of research, 1H-Benzimidazole, 2-chloro-7-(trifluoromethyl)is utilized as a chemical probe to study the mechanisms of action of various biological processes. Its diverse biological activities allow researchers to investigate its potential effects on different cellular pathways and explore its applications in drug discovery.
Used in Organic Synthesis:
1H-Benzimidazole, 2-chloro-7-(trifluoromethyl)serves as a valuable building block in organic synthesis, enabling the creation of a wide range of organic compounds with potential applications in various industries, such as pharmaceuticals, agrochemicals, and materials science.
Used in Drug Discovery:
Due to its potential medicinal properties, 1H-Benzimidazole, 2-chloro-7-(trifluoromethyl)is a target for drug discovery, where it can be further modified or used as a starting point for the development of new therapeutic agents with improved efficacy and selectivity.

Upstream product

• 88-17-5 2-(trifluoromethyl)benzenamine 
• 444-93-9 (E)-2-(hydroxyimino)-N-(2-(trifluoromethyl)phenyl)acetamide 
• 391-12-8 7-trifluoromethylisatin 
• 313-12-2 2-amino-3-(trifluoromethyl)benzoic acid 
• 887144-97-0 Togni's reagent 
• 4857-06-1 2-chloro-1H-benzoimidazole 
• 360-60-1 3-(trifluoromethyl)benzene-1,2-diamine 
• 2251-78-7 4-(trifluoromethyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one 

Relevant academic research and scientific papers

Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof

The invention discloses a benzenesulfonamide compound represented by a general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. Compared with the prior art, the benzenesulfonamide compound disclosed by the invention can be used as an isocitrate dehydrogenase 2 (IDH2) mutant inhibitor. According to the invention, pharmacological experiment results show that the compound disclosed by the invention has an obvious inhibiting effect on the activity of an IDH2 mutant (mIDH2), can effectively inhibit the process of catalyzing alpha-ketoglutaricacid to generate 2-hydroxyglutaric acid by mIDH2, and can be used for preventing and/or treating various related diseases including cancers and the like caused by IDH2 mutation.

Selective C-H trifluoromethylation of benzimidazoles through photoredox catalysis

The protocol presented here is a new strategy for visible light induced C-H trifluoromethylation at C4 of benzimidazoles using Togni's reagent in the presence of fac-Ir(ppy)3. Its advantages are its operational simplicity, mild reaction conditions, low catalyst loading and wide substrate scope in which electron-withdrawing, electron-donating groups and different protecting groups are tolerated.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

There are disclosed a series of quinuclidines having the Formula (I). which bind to the nicotinic α7 receptor and may be useful for the treatment of disorders of the central nervous system.

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright